Therefore, this systematic review and meta-analysis aimed to synthesize the evidence from the recent RCTs, investigating the efficacy and safety of once-weekly insulin icodec vs once-daily long-acting insulin (insulin glargine and insulin degludec) in T2D patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.